Related Experiment Videos
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group
Insights
The Aspirin Myocardial Infarction Study found that daily aspirin did not reduce overall mortality after a heart attack. Aspirin use also increased gastrointestinal issues, leading to no recommendation for its routine use post-myocardial infarction.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Myocardial infarction (MI) survivors require effective secondary prevention strategies.
- The role of aspirin in reducing mortality and reinfarction after MI has been a subject of clinical investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of daily aspirin administration in patients following a documented myocardial infarction.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled trial involving 4524 participants aged 30-69 years.
- Participants received either 1.0 g of aspirin daily or a placebo.
Main Results:
- Total mortality was 10.8% in the aspirin group versus 9.7% in the placebo group (nonsignificant trend).
- Nonfatal myocardial infarction showed a nonsignificant trend towards lower incidence in the aspirin group (6.3%) compared to placebo (8.1%).
- Gastrointestinal irritation symptoms were more frequent in the aspirin group (23.7%) than the placebo group (14.9%).
Conclusions:
- Routine use of aspirin after myocardial infarction is not recommended based on the AMIS trial findings.
- The observed increase in gastrointestinal adverse effects outweighs the nonsignificant trends in mortality and reinfarction reduction.
Abstract:
The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1.0 g of aspirin daily in men and women who had had a documented myocardial infarction. In the trial 4524 persons, ages 30-69 years, were recruited; 2267 were randomized to aspirin and 2257 to placebo. The major end point, total mortality, was 10.8% in the aspirin group and 9.7% in the placebo group. There was a nonsignificant trend indicating a lower incidence of nonfatal myocardial infarction in the aspirin group (6.3%) compared with the placebo group (8.1%). Symptoms suggestive of gastrointestinal irritation appeared in 23.7% of the aspirin group and in 14.9% of the placebo group. Based on these findings, routine use of aspirin after myocardial infarction is not recommended.